Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 FDA Authorizes Roche's COVID-19 Test that Can Detect Viral Load - Medical Product Outsourcing
OEM News

FDA Authorizes Roche’s COVID-19 Test that Can Detect Viral Load

The automated, RT-PCR assay allows in-vitro qualitative and quantitative SARS-CoV-2 RNA detection.

Roche has gained U.S. Food and Drug Administration (FDA) emergency use authorization (EUA) for its cobas SARS-CoV-2 Duo for use on the fully automated cobas 6800/8800 Systems.
 
The automated, RT-PCR assay allows in-vitro qualitative and quantitative SARS-CoV-2 RNA detection in nasal and nasopharyngeal swab specimens.
 
“With the SARS-CoV-2 Duo test, we are now able to detect the COVID-19 virus and simultaneously measure the viral load in an individual,” Thomas Schinecker, CEO of Roche Diagnostics told the press. “The test’s performance suggests that, by earlier and more accurately identifying infected patients, the results may open the path for healthcare providers to more efficiently organize their therapeutic and monitoring interventions.”
 
Reporting a standardized viral load along with the qualitative result can help clinicians assess and monitor infected patients across labs and over time. The test will be available by the end of Q2.

Add us as a preferred source on Google

Get the latest Medical Product Outsourcing news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Medical Product Outsourcing Newsletters